세계의 의약품 ADMET 시험 시장 보고서(2025년)
Pharma ADMET Testing Global Market Report 2025
상품코드 : 1824436
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 250 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ₩ 6,664,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ₩ 9,632,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ₩ 12,600,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

의약품 ADMET 시험 시장 규모는 향후 수년간 급성장할 것으로 전망됩니다. 2029년에는 CAGR 12.3%로 성장할 전망이며, 170억 3,000만 달러로 성장이 예측됩니다. 예측 기간의 성장은 환경독성학 및 안전성 평가, 파마코유전체학의 인식, 정밀의료에 대한 주력, 생물제제 및 바이오시밀러의 성장, 인공지능(AI)의 통합, 규제 요건의 확대, 희소질병용 의약품 개발 증가에 기인할 것으로 보입니다. 예측 기간 주요 동향으로는 공동연구 증가, 급속한 기술 혁신, 분석기술 진보, 의약품의 안전성의 지속적인 모니터링, 환경에 대한 영향에 대한 배려 등을 들 수 있습니다.

향후 5년간의 성장률 12.3%라고 하는 예측은 전회 예측으로부터 0.1%라고 하는 미감소를 반영하고 있습니다. 이 감소는 주로 미국과 타국가 간 관세의 영향 때문입니다. 관세의 상승은 벨기에나 일본에서 조달하는 하이 스루풋 ADMET 스크리닝 시스템이나 3D 간 마이크로 티슈의 비용을 끌어올려, 연구 개발비를 악화시켜, 신약의 승인을 늦추는 것으로, 미국의 의약품 개발 기업에 부담을 강하게 할 가능성이 높습니다. 또한 상호관세와 무역 긴장 증가 및 제한 증가로 인한 세계 경제와 무역에 대한 악영향으로 그 영향이 더욱 광범위해질 것으로 보입니다.

제품 승인 수 증가가 의약품 ADMET 시험 시장의 성장에 박차를 가하고 있습니다. 제품 승인이란 미국 식품의약국(FDA)과 유럽의 유럽의약청(EMA) 등 규제당국이 일반 대중에게 제품의 판매 및 마케팅을 인가하는 프로세스를 말합니다. ADMET 시험은 신제품의 안전성과 유효성을 평가하는 데 필수적이며 규제 당국의 승인에 필수적인 요건입니다. 예를 들어, 2024년 1월 미국에 본사를 둔 생물의학 도서관이며 의료 전문가를 위한 국가 자원인 국립의학 도서관은 미국 식품의약국(FDA)이 2023년에 승인한 신약은 55개 품목이며 2022년에 승인된 37개 품목에서 증가하고 있다고 보고했습니다. 그러므로 제품 승인 수 증가는 의약품 ADMET 시험 시장을 견인하고 있습니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향 및 전략

제4장 시장 : 금리, 인플레이션, 지정학, 무역전쟁 및 관세, 그리고 코로나 및 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석 및 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별 및 국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도 및 기업 프로파일

제31장 기타 주요 기업 및 혁신 기업

제32장 세계 시장 경쟁 벤치마킹 및 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 부문 및 전략

제36장 부록

AJY
영문 목차

영문목차

Pharmaceutical ADMET testing encompasses a series of methodologies and assays employed in the pharmaceutical sector to evaluate the Absorption, Distribution, Metabolism, Excretion, and Toxicity (ADMET) characteristics of drug candidates. This essential process is instrumental in gauging the safety and effectiveness of prospective drugs prior to obtaining regulatory approval for clinical application.

The primary categories of pharma ADMET testing include in vivo ADMET testing, in vitro ADMET testing, and in silico ADMET testing. In vivo ADMET testing involves the analysis of a drug's absorption, distribution, metabolism, excretion, and toxicity attributes within a living organism. Widely utilized throughout drug discovery and development phases, pharma ADMET testing plays a crucial role in pinpointing potential drug candidates endowed with favorable pharmacokinetic properties. Utilizing advanced technologies such as cell culture, high throughput, molecular imaging, and OMICS, pharma ADMET testing is pivotal in assessing systemic toxicity, renal toxicity, hepatotoxicity, neurotoxicity, and other relevant parameters. This comprehensive approach aids in the strategic identification of drug candidates that align with desired efficacy and safety profiles, thereby contributing to informed decision-making in the pharmaceutical business landscape.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.

The pharma ADMET testing market research report is one of a series of new reports from The Business Research Company that provides pharma ADMET testing market statistics, including the pharma ADMET testing industry's global market size, regional shares, competitors with a pharma ADMET testing market share, detailed pharma ADMET testing market segments, market trends, and opportunities, and any further data you may need to thrive in the pharma ADMET testing industry. This pharma ADMET testing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The pharma admet testing market size has grown rapidly in recent years. It will grow from $9.67 billion in 2024 to $10.7 billion in 2025 at a compound annual growth rate (CAGR) of 10.6%. The growth in the historic period can be attributed to growth in biopharmaceuticals and biosimilars, rise in drug development activities, growing awareness of drug safety, globalization of clinical trials, shift towards in silico modeling.

The pharma admet testing market size is expected to see rapid growth in the next few years. It will grow to $17.03 billion in 2029 at a compound annual growth rate (CAGR) of 12.3%. The growth in the forecast period can be attributed to environmental toxicology and safety assessment, awareness of pharmacogenomics, focus on precision medicine, growth of biologics and biosimilars, integration of artificial intelligence (AI), expanded regulatory requirements, rise in orphan drug development. Major trends in the forecast period include increasing collaboration in research, rapid technological innovations, advancements in analytical technologies, continuous monitoring of drug safety, and environmental impact considerations.

The forecast of 12.3% growth over the next five years reflects a slight reduction of 0.1% from the previous projection. This reduction is primarily due to the impact of tariffs between the US and other countries. Tariff escalations are likely to burden U.S. drug developers by driving up the cost of high-throughput ADMET screening systems and 3D liver microtissues sourced from Belgium and Japan, exacerbating R&D expenses and delaying new drug approvals. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The increasing number of product approvals is fueling the growth of the pharma ADMET testing market. Product approvals refer to the process through which regulatory authorities, such as the Food and Drug Administration (FDA) in the United States or the European Medicines Agency (EMA) in Europe, authorize a product for marketing and sale to the public. ADMET testing is essential for assessing the safety and efficacy of new products and is a requirement in regulatory approvals. For example, in January 2024, the National Library of Medicine, a US-based biomedical library and a national resource for health professionals, reported that the U.S. Food and Drug Administration (FDA) approved 55 new drugs in 2023, an increase from 37 drugs approved in 2022. Therefore, the rising number of product approvals is driving the pharma ADMET testing market.

The surge in clinical trials is expected to drive the pharma ADMET testing market's growth in the future. Clinical trials, essential research studies involving human participants, evaluate the safety, efficacy, and potential side effects of medical interventions, including new drugs, medical devices, diagnostic procedures, or treatment regimens. The escalating number of clinical trials significantly amplifies the demand for comprehensive assessments of drug safety and efficacy within the pharma ADMET testing market. For example, a report from Xtalks reveals that, as of May 2023, there are 452,604 registered clinical studies on ClinicalTrials.gov, indicating a notable increase from the over 365,000 trials recorded in early 2021. This uptick underscores the industry's growing need for tailored evaluations across diverse drug candidates and patient populations, thereby propelling the pharma ADMET testing market's expansion.

A prominent trend gaining traction in the pharma ADMET testing market is the focus on product innovations, with major companies introducing cutting-edge solutions to enhance their market position. Notably, Charles River Laboratories International Inc. and Valo Health Inc. launched Logica in April 2022-an AI-based drug development solution. Leveraging Valo's Opal Computational Platform, Logica provides users with ADMET testing services and other drug delivery solutions. The solution incorporates industry-leading predictive models, chemical design and synthesis capabilities, DNA-encoded libraries, and in silico high-throughput screening. Charles River's expertise in various discovery optimization aspects, including high-throughput screening, medicinal chemistry, ADME, biology, pharmacology, safety testing, and IND submission, further enhances Logica's capabilities.

Major players in the pharma ADMET testing market are strategically engaging in partnerships to advance efforts in discovering allosteric drugs. An illustrative example is the collaboration between Excelra and HotSpot Therapeutics Inc. In May 2022, Excelra, specializing in accelerating drug discovery through advanced data science, partnered with HotSpot Therapeutics Inc., a biotechnology company focused on small molecule allosteric therapies. This strategic alliance involves integrating Excelra's product, GOSTAR, and its annotated datasets into HotSpot's machine learning (ML) and artificial intelligence (AI) models. GOSTAR, with insights into over 8 million small molecules, provides comprehensive information on chemical structures and various biological properties, facilitating the exploration and development of small molecule therapeutic candidates targeting challenging allosteric sites.

In September 2022, BioIVT, a prominent drug development solutions provider based in the United States, successfully completed the acquisition of XenoTech for an undisclosed sum. This strategic move is designed to enhance BioIVT's product portfolio by integrating XenoTech's capabilities and to facilitate the expansion of its product offerings into new geographic regions, thereby reaching a broader customer base. XenoTech, a respected US-based contract research organization, specializes in offering ADMET (Absorption, Distribution, Metabolism, Excretion, and Toxicity) testing services. This acquisition underscores BioIVT's commitment to strengthening its position in the drug development sector by incorporating complementary expertise and extending its reach to cater to evolving market demands.

Major companies operating in the pharma ADMET testing market include Thermo Fisher Scientific Inc., The Merck Group, Laboratory Corporation of America Holdings, IQVIA Inc., PPD ICON plc, Agilent Technologies Inc., Wuxi AppTec Co. Ltd., Catalent Inc., Covance Inc., Charles River Laboratories International Inc., Eurofins Scientific SE, Beckman Coulter Inc., Perkinelmer Inc., Albany Molecular Research Inc., Evotec A.G., CMIC Holdings Co. Ltd., Promega Corporation, Aptuit LLC, Symeres B.V., Biovia Corp., BioIVT LLC, Cyprotex Limited, InSphero AG, Admescope Ltd., Accelrys Inc.

Asia-Pacific was the largest region in the pharma ADMET testing market in 2024. The regions covered in the pharma admet testing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the pharma admet testing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The pharma ADMET testing market consists of revenues earned by entities by providing services such as in vitro screening, in vitro metabolism, and metabolite testing. The market value includes the value of related goods sold by the service provider or included within the service offering. The pharma ADMET testing market also includes the sales of membranes, buffer systems, and analytes that are used in the assays. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Pharma ADMET Testing Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on pharma admet testing market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for pharma admet testing ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The pharma admet testing market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

Scope

Table of Contents

1. Executive Summary

2. Pharma ADMET Testing Market Characteristics

3. Pharma ADMET Testing Market Trends And Strategies

4. Pharma ADMET Testing Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Pharma ADMET Testing Growth Analysis And Strategic Analysis Framework

6. Pharma ADMET Testing Market Segmentation

7. Pharma ADMET Testing Market Regional And Country Analysis

8. Asia-Pacific Pharma ADMET Testing Market

9. China Pharma ADMET Testing Market

10. India Pharma ADMET Testing Market

11. Japan Pharma ADMET Testing Market

12. Australia Pharma ADMET Testing Market

13. Indonesia Pharma ADMET Testing Market

14. South Korea Pharma ADMET Testing Market

15. Western Europe Pharma ADMET Testing Market

16. UK Pharma ADMET Testing Market

17. Germany Pharma ADMET Testing Market

18. France Pharma ADMET Testing Market

19. Italy Pharma ADMET Testing Market

20. Spain Pharma ADMET Testing Market

21. Eastern Europe Pharma ADMET Testing Market

22. Russia Pharma ADMET Testing Market

23. North America Pharma ADMET Testing Market

24. USA Pharma ADMET Testing Market

25. Canada Pharma ADMET Testing Market

26. South America Pharma ADMET Testing Market

27. Brazil Pharma ADMET Testing Market

28. Middle East Pharma ADMET Testing Market

29. Africa Pharma ADMET Testing Market

30. Pharma ADMET Testing Market Competitive Landscape And Company Profiles

31. Pharma ADMET Testing Market Other Major And Innovative Companies

32. Global Pharma ADMET Testing Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Pharma ADMET Testing Market

34. Recent Developments In The Pharma ADMET Testing Market

35. Pharma ADMET Testing Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기